AnGes : filed for approval of its HGF gene therapy product Collategene® for the first time since the introduction of the conditional/time-limited authorization system for regenerative medicine products

May 31, 2023


Company Name: AnGes Inc.


Presentative: Ei Yamada, President & CEO

... | May 31, 2023

Related Keywords

Ibaraki ,Osaka ,Japan ,United States ,Chuo Ku ,Tokyo ,Israel ,Japanese ,Akihiro Tsujimura ,Anges Inc ,Ministry Of Health ,Mitsubishi Tanabe Pharma Corporation Chemical Group ,Air Group ,Mitsubishi Tanabe Pharma Corporation ,Mitsubishi Tanabe Pharma Corporation Head Office ,Corporate Communications ,Anges Head Office ,Mitsubishi Chemical Group ,Osaka Corporate Communications Dept ,Affairs Law ,Company Name ,Marketing Approval Application ,Therapy Product Collategene ,Intramuscular Injection ,Pharmaceutical Affairs Law ,Hepatocyte Growth Factor ,Head Office ,Representative Director ,Tanabe Pharma Corporation ,Medical Devices Law ,Public Relations ,Osaka Corporate Communications ,Oranges ,Nc Stock Exchange ,News ,Information ,Press Release ,Bay ,Company ,Songes ,Hi ,Resident 4563 Jp3127700007 ,